Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Пересмотренные критерии диагностики и стадирования болезни Альцгеймера: рабочая группа Ассоциации Альцгеймера
2024-06-27
SCID: 54.1/98fr84z4
Discuss with AI
Alzheimer's diseaseamyloid PETbiomarkerscerebrospinal fluid biomarkersphosphorylated tau 217
Figures from the paper
Abstract (AI)
The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). The present document updates the 2018 research framework in response to several recent developments. Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD. The present document is consistent with this principle. Our intent is to present objective criteria for diagnosis and staging AD, incorporating recent advances in biomarkers, to serve as a bridge between research and clinical care. These criteria are not intended to provide step-by-step clinical practice guidelines for clinical workflow or specific treatment protocols, but rather serve as general principles to inform diagnosis and staging of AD that reflect current science. HIGHLIGHTS: We define Alzheimer's disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms. Early-changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway; however, these reflect the presence of ADNPC more generally (i.e., both neuritic plaques and tangles). An abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making throughout the disease continuum. Later-changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms. An integrated biological and clinical staging scheme is described that accommodates the fact that common copathologies, cognitive reserve, and resistance may modify relationships between clinical and biological AD stages.
Key Findings
1
Alzheimer’s disease is defined biologically as a process beginning with Alzheimer’s disease neuropathologic change before symptoms appear.
2
An abnormal Core 1 biomarker is sufficient to establish an Alzheimer’s disease diagnosis and support clinical decision-making across the disease continuum.
3
Disease progression reflects increasing neuropathologic burden followed by the emergence and worsening of clinical symptoms.
4
Early-changing Core 1 biomarkers, including amyloid PET, approved cerebrospinal fluid markers, and especially phosphorylated tau 217, identify Alzheimer’s disease pathology.
5
Later-changing Core 2 fluid and tau PET biomarkers provide prognostic information and increase confidence that Alzheimer’s disease contributes to clinical impairment when abnormal.
6
The revised criteria incorporate advances in biomarkers to bridge research and clinical care, while not prescribing specific clinical workflows or treatment protocols.
Research Object
Alzheimer's disease as a biological process across its disease continuum
Research Subject
Biomarker-based biological diagnosis and staging of Alzheimer's disease, including the temporal progression of amyloid and tau pathology and associated clinical symptoms
Publication Details
Publication Date
2024-06-27
Journal
Publisher
ISSN
Cited by
2775
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review2013
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease2011
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease2018
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease2011
Current Concepts in Mild Cognitive Impairment2001
Alzheimer's disease drug development pipeline: 20212021
Longitudinal tau PET in ageing and Alzheimer’s disease2018